CSI Market
Sign In | Register

Barinthus Biotherapeutics Plc (BRNS) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access BRNS Annual Cash Flow →
Changes in quarterly cash flow trends offer perspective on how Barinthus Biotherapeutics Plc funds operations, investments, and shareholder returns.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-16.13
Depreciation & amortization1.68
Amortization of Other Assets1.20
Increase (Decrease) in Deferred Revenue-1.05
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability0.17
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.07
Share-based Compensation0.99
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), Unrealized3.37
Right Of Use Asset Obtained In Exchange For Operating Lease Liability-
Embedded Derivative Gain Loss On Embedded Derivative Net-
Non Cash Interest Expense On Convertible Loan Notes0.01
Increase Decrease In Research And Development Incentives Receivable-0.15
Non Cash Lease Expenses0.21
Impairment Long Lived Asset Held For Use Use And Operating Lease Impairment Loss-
Asset Impairment Charges Excluding Goodwill-
Increase Decrease In Operating Lease Liability-0.35
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable0.19
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities2.69
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-2.44
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net-0.02
Payments for (Proceeds from) Other Operating Activities-2.17
Discontinued operations0.00
Net Cash flow from Operating Activities-11.46
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.12
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.12
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Payments Of Transaction Costs For Redeemable Convertible Preferred Stock-
Proceeds From Issuance Of Ordinary Shares Net Of Underwriters Fees-
Proceeds From Issuance Or Sale Of Equity-
Increase Decrease In Equity From Noncontrolling Interest-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-0.88
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-11.34
Total Cash Flow-12.22
4 historic quarters locked

Sign in to unlock the full Barinthus Biotherapeutics Plc cash flow history.

Sign In Create Free Account

About Barinthus Biotherapeutics Plc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-053933

Figures are derived from filed reports and may be restated. Historical data is subject to revision.